1. Home
  2. APRE vs JBDI Comparison

APRE vs JBDI Comparison

Compare APRE & JBDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • APRE
  • JBDI
  • Stock Information
  • Founded
  • APRE 2006
  • JBDI 1983
  • Country
  • APRE United States
  • JBDI Singapore
  • Employees
  • APRE N/A
  • JBDI N/A
  • Industry
  • APRE Biotechnology: Biological Products (No Diagnostic Substances)
  • JBDI
  • Sector
  • APRE Health Care
  • JBDI
  • Exchange
  • APRE Nasdaq
  • JBDI Nasdaq
  • Market Cap
  • APRE 15.8M
  • JBDI 13.6M
  • IPO Year
  • APRE 2019
  • JBDI 2024
  • Fundamental
  • Price
  • APRE $3.05
  • JBDI $0.58
  • Analyst Decision
  • APRE Strong Buy
  • JBDI
  • Analyst Count
  • APRE 2
  • JBDI 0
  • Target Price
  • APRE $15.50
  • JBDI N/A
  • AVG Volume (30 Days)
  • APRE 22.6K
  • JBDI 174.7K
  • Earning Date
  • APRE 11-07-2024
  • JBDI 02-15-2025
  • Dividend Yield
  • APRE N/A
  • JBDI N/A
  • EPS Growth
  • APRE N/A
  • JBDI N/A
  • EPS
  • APRE N/A
  • JBDI N/A
  • Revenue
  • APRE $1,310,839.00
  • JBDI $9,394,000.00
  • Revenue This Year
  • APRE $134.21
  • JBDI N/A
  • Revenue Next Year
  • APRE N/A
  • JBDI N/A
  • P/E Ratio
  • APRE N/A
  • JBDI N/A
  • Revenue Growth
  • APRE 130.31
  • JBDI N/A
  • 52 Week Low
  • APRE $2.15
  • JBDI $0.51
  • 52 Week High
  • APRE $8.85
  • JBDI $39.41
  • Technical
  • Relative Strength Index (RSI)
  • APRE 43.20
  • JBDI N/A
  • Support Level
  • APRE $3.02
  • JBDI N/A
  • Resistance Level
  • APRE $3.39
  • JBDI N/A
  • Average True Range (ATR)
  • APRE 0.30
  • JBDI 0.00
  • MACD
  • APRE -0.01
  • JBDI 0.00
  • Stochastic Oscillator
  • APRE 3.85
  • JBDI 0.00

About APRE Aprea Therapeutics Inc. Common stock

Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.

About JBDI JBDI Holdings Limited Ordinary Shares

JBDI Holdings Ltd is a supplier of Reconditioned and new Containers in Singapore. Its products include Reconditioned and new steel drums, plastic drums, carboys and IBCs.

Share on Social Networks: